

## DOCTORAL THESIS

### A mechanistic study on the use of the TCM formula si-jun-zi-tang as an adjuvant anti-melanoma agent

Wang, Yaping

*Date of Award:*  
2020

[Link to publication](#)

#### **General rights**

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

## ABSTRACT

Melanoma is among the most aggressive and treatment-resistant cancers. Currently, available therapies for melanoma are not satisfactory, and the prognosis for patients with metastatic melanoma is still poor. Vemurafenib, a BRAF kinase inhibitor (BRAFi), provides an approximately 50% response rate in patients with metastatic melanoma, but eventually, relapse occurs due to acquired resistance to the drug. Novel therapeutics and BRAFi adjuvants for treating melanoma are needed. *Si-Jun-Zi-Tang* (SJZT) is a traditional Chinese medicine formula used to treat chronic and debilitating diseases including melanoma. SJZT-based therapies alone or in combination with chemotherapies have achieved good clinical outcomes in melanoma management. However, the pharmacological basis of SJZT for its clinical use in melanoma treatment is not fully understood. c-Met is a receptor tyrosine kinase (RTK), and hepatocyte growth factor (HGF) is the only known ligand of c-Met. Abnormal activation of HGF/c-Met has been implicated in melanoma progression. HGF/c-Met has been proposed as a therapeutic target for melanoma. Some bioactive constituents in SJZT have been shown to inhibit c-Met signaling. In this study, we investigated the anti-melanoma effects and c-Met signaling-related action mechanisms of SJZT.

Our *in vivo* study showed that SJZT-A, an ethanolic extract of SJZT, inhibited B16 tumor growth in mice without overt toxicity. Mechanistic investigations revealed that SJZT-A elevated miR-34b (a tumor-suppressing miRNA), and lowered c-Met (a miR-34b target gene) and  $\beta$ -catenin (a downstream molecule of c-Met signaling) expression levels in the B16 tumors. But SJZT-A failed to reduce the viability of B16 and A375 melanoma cells. Active component-enriched SJZT-B, which was prepared from SJZT-A using macroporous resin column chromatography, exhibited potent anti-proliferation effect and inhibited miR-34b/c-Met/ $\beta$ -catenin signaling in cultured melanoma cells. Overexpression of constitutively active  $\beta$ -catenin partially diminished the inhibitory effect of SJZT-B

on cell proliferation. SJZT-B also exerted anti-proliferative effects, inhibited c-met signaling, and induced ER stress in vemurafenib resistance melanoma cells. *In vivo* experiments showed that intragastric administration of SJZT-B for consecutive 14 days overcame vemurafenib resistance in melanoma-bearing mice without observable toxicities. Overall, these results indicate that SJZT has anti-melanoma effects and is relatively safe.

Also, we found that licochalcone A, a flavonoid presented in SJZT-B, overcame vemurafenib resistance both *in vitro* and *in vivo*, as well as inhibited c-Met signaling and induced ER stress in A375-VR cells, which is in line with the effects of SJZT-B in melanoma. The role of triggering ER stress in licochalcone A's effects in overcoming vemurafenib resistance effects has also been established. Overall, these results suggest that licochalcone A is one of the active compounds responsible for the anti-melanoma effects of SJZT-B.

In conclusion, our results demonstrated that SJZT has anti-melanoma effects and is safe in cell and mouse melanoma models. Licochalcone A has been identified to be one of the active components responsible for the anti-melanoma effects of SJZT. This study provides a pharmacological and chemical basis for the traditional use of the formula SJZT in treating melanoma, and suggests that SJZT and SJZT-derived compounds have the potential to be developed as modern alternative and/or complementary agents for melanoma management.

**Key words:** *Si-Jun-Zi-Tang*; traditional Chinese medicine; melanoma; miR-34b; c-Met;  $\beta$ -catenin, ER stress, licochalcone A

## TABLE OF CONTENTS

<b><u>DECLARATION</u></b> .....	i
<b><u>ABSTRACT</u></b> .....	ii
<b><u>ACKNOWLEDGMENTS</u></b> .....	iv
<b><u>LIST OF TABLES</u></b> .....	ix
<b><u>LIST OF FIGURES</u></b> .....	x
<b><u>LIST OF ABBREVIATIONS</u></b> .....	xii
<b><u>CHAPTER 1 General introduction</u></b> .....	1
<u>1.1 Melanoma</u> .....	1
1.1.1 Epidemiology.....	1
1.1.2 Pathobiology .....	4
1.1.3 Treatments .....	14
1.2 Traditional Chinese medicine (TCM) and melanoma .....	22
1.3 Si-Jun-Zi-Tang (SJZT) .....	23
1.3.1 Clinical application .....	23
1.3.2 Pharmacological research .....	25
1.3.3 Bioactive components of SJZT.....	29
1.4 Hypothesis and objectives .....	31
<b><u>CHAPTER 2 Materials and methods</u></b> .....	32
2.1 Herbal materials.....	32
2.2 Other materials.....	32
2.3 Quality control of SJZT-A and SJZT-B .....	34
2.4 UPLC analysis .....	35
2.5 Cell culture.....	35
2.6 Melanoma-bearing mouse models .....	35
2.7 Western blot analysis .....	37
2.8 microRNA array analysis.....	38

<u>2.9 Real-time quantitative polymerase chain reaction (RT-qPCR) analysis</u>	38
<u>2.10 Cell viability assays</u>	39
<u>2.11 Human phospho-receptor tyrosine kinase (Phospho-RTK) array</u>	40
<u>2.12 Establishment of stable cell lines</u>	40
<u>2.13 Morphologic changes</u>	40
<u>2.14 RNA-Sequencing (RNA-seq)</u>	41
<u>2.15 Statistical analysis</u>	41
<b><u>CHAPTER 3 SJZT exerts anti-melanoma effects <i>in vitro</i> and <i>in vivo</i></u></b>	<b>42</b>
<u>3.1 Abstract</u>	42
<u>3.2 Results</u>	43
<u>3.2.1 Preparation of 50% ethanol extract of SJZT (SJZT-A)</u>	43
<u>3.2.2 Quality control of SJZT-A</u>	44
<u>3.2.3 SJZT-A inhibits B16 allograft melanoma growth in mice</u>	47
<u>3.2.4 miRNA array analysis</u>	49
<u>3.2.5 SJZT-A lowers the expression level of c-Met in B16 tumors</u>	53
<u>3.2.6 SJZT-A lowers the expression level of <math>\beta</math>-Catenin in B16 tumors</u>	54
<u>3.2.7 SJZT-A fails to reduce the viability of melanoma cells</u>	55
<u>3.2.8 Enrichment of the active constituents of SJZT-A</u>	56
<u>3.2.9 The 95% ethanol fraction of SJZT-A (SJZT-B) reduces the viability of melanoma cells</u>	58
<u>3.2.10 Quality control of SJZT-B</u>	60
<u>3.2.11 SJZT-B inhibits miR-34b/c-Met/<math>\beta</math>-catenin signaling in melanoma cells</u>	62
<u>3.2.12 Overexpression of <math>\beta</math>-catenin diminishes the effects of SJZT-B on cell proliferation</u>	64
<u>3.2.13 SJZT-B overcomes vemurafenib resistance in melanoma cells</u>	65
<u>3.2.14 SJZT-B inhibits c-Met signaling in vemurafenib-resistant melanoma cells</u>	67

<u>3.2.15 SJZT-B induces ER stress in vemurafenib-resistant melanoma cells</u> .....	71
<u>3.2.16 SJZT-B overcomes vemurafenib resistance <i>in vivo</i></u> .....	73
<u>3.3 Summary</u> .....	75
<b><u>CHAPTER 4 Licochalcone A, an active compound in SJZT-B, exerts anti-melanoma effects</u></b> .....	77
<u>4.1 Abstract</u> .....	77
<u>4.2 Results</u> .....	78
<u>4.2.1 Licochalcone A is a flavonoid that can be detected in SJZT-B</u> ....	78
<u>4.2.2 Licochalcone A overcomes vemurafenib resistance <i>in vitro</i></u> .....	83
<u>4.2.3 Licochalcone A inhibits c-Met signaling in melanoma cells</u> .....	84
<u>4.2.4 Licochalcone A triggers ER stress in A375-VR cells</u> .....	86
<u>4.2.5 Inhibiting ER stress with 4-PBA diminishes the cytotoxic effect of licochalcone A in A375-VR cells</u> .....	88
<u>4.2.6 Licochalcone A overcomes vemurafenib resistance in melanoma-bearing mice</u> .....	89
<u>4.3 Summary</u> .....	91
<b><u>Chapter 5 General discussion, conclusion, and future plans</u></b> .....	92
<u>5.1 General discussion and conclusion</u> .....	92
<u>5.2 Significance of this study</u> .....	97
<u>5.3 Future plans</u> .....	97
<u>5.3.1 To explore the involvement of other SJZT-A-altered miRNAs in the anti-melanoma action of SJZT-A</u> .....	97
<u>5.3.2 To complete the story of the effects of SJZT-B in overcoming vemurafenib resistance in melanoma</u> .....	98
<u>5.3.3 To complete the study on the anti-melanoma mode and mechanisms of licochalcone A</u> .....	99
<b><u>REFERENCES</u></b> .....	101
<b><u>PUBLICATIONS</u></b> .....	151

**CURRICULUM VITAE**.....158